Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1961-1980 of 2,120 trials

Worsening Heart Failure: COR-1167 Treatment Study

We are testing a new medication for people with worsening heart failure to see how it affects symptoms and heart health. The study will also check the safety and tolerability of this treatment.

Worsening Heart Failure≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Chronic Graft-Versus-Host Disease: Axatilimab Treatment Study

We are comparing a new treatment called axatilimab to the best available therapy for patients with chronic graft-versus-host disease who have not responded to previous treatments. The goal is to see if axatilimab is more effective and safer.

Chronic Graft-Versus-Host Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Colorectal Cancer: FOLFIRI and Cetuximab Treatment

We are studying whether a combination of FOLFIRI and Cetuximab is effective for patients with advanced colorectal cancer who have specific genetic markers. This research aims to improve first-line treatment options for these patients.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Clear-Cell Renal Carcinoma: Digital Monitoring with Cabozantinib and Nivolumab

We are studying how digital tracking of symptoms can help adjust treatments for patients with advanced clear-cell renal carcinoma receiving Cabozantinib and Nivolumab. This may improve their overall health and quality of life during treatment.

Kidney Cancer>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncologyUrology

Ulcerative Colitis: Comparing Risankizumab and Vedolizumab

We are studying whether risankizumab is more effective and safe than vedolizumab for adults with moderate to severe ulcerative colitis who have not yet received targeted treatments.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Locally Advanced Rectal Cancer: NeoAspMet Trial

We are studying whether adding aspirin or metformin to standard chemotherapy improves tumor response in patients with locally advanced rectal cancer. This trial aims to see if these treatments can lead to better outcomes compared to standard care.

Locally Advanced Rectal CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Pleural Mesothelioma: Ivonescimab Treatment Study

We are evaluating ivonescimab for patients with relapsing pleural mesothelioma who have already been treated with immunotherapy and chemotherapy. The study aims to assess its safety and effectiveness as a potential new treatment option.

Pleural Mesothelioma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Heart Failure: Ferric Derisomaltose Treatment

We are studying whether ferric derisomaltose can improve heart health and reduce hospitalizations in people with iron deficiency and chronic heart failure. This trial compares it to no intravenous iron treatment.

Chronic Heart Failure1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Chronic Hepatitis Delta: Brelovitug Treatment Study

We are studying a new medication, brelovitug, for people with chronic hepatitis delta infection. The trial aims to see if it works better than waiting for treatment and to evaluate its safety.

Hepatitis D>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatology

Gastric Cancer: Pre-operative Treatment with Capecitabine and Atezolizumab

We are studying a combination of chemotherapy and immunotherapy for patients with resectable gastric and GE-junction cancer. The goal is to see if this treatment is safe and effective in shrinking tumors before surgery.

Gastric Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Atopic Dermatitis: Investigational Compounds Study

We are evaluating new treatments for moderate to severe atopic dermatitis to see if they improve skin symptoms better than a placebo. The study also looks at the safety of these treatments.

Atopic Dermatitis3-6 monthsEfficacy phase (II)Investigational MedicinesAllergologyDermatology

Neuroblastoma: Innovative Stem Cell Transplant and Immunotherapy

We are studying a new stem cell transplant method followed by immunotherapy for children with relapsed or resistant high-risk neuroblastoma. This trial aims to evaluate the safety and effectiveness of this approach in improving treatment outcomes.

Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Felzartamab for Kidney Transplant Recipients with Late Antibody-Mediated Rejection

We are studying whether felzartamab can improve outcomes for kidney transplant recipients facing late antibody-mediated rejection. This trial compares the new treatment to a placebo to assess its effectiveness and safety.

Kidney Transplant Rejection1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNephrology

Esketamine for Schizophrenia Symptoms

We are studying whether esketamine can reduce depressive and negative symptoms in people with schizophrenia. The trial also looks at whether it causes any worsening of psychotic symptoms.

Negative and Depressive Symptoms in Schizophrenia and Schizoaffective Disorder≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPsychiatry

Tozorakimab for Uncontrolled Asthma

We are studying whether different doses of tozorakimab can help adults with uncontrolled asthma reduce severe attacks. This trial compares the medication to a placebo to evaluate its effectiveness and safety.

Asthma1-2 yearsEfficacy phase (II)Investigational MedicinesPartially RemoteAllergologyPulmonology

High-Risk Thyroid Cancer: Neoadjuvant Pembrolizumab Study

We are studying the effects of pembrolizumab as a pre-surgery treatment for patients with high-risk thyroid cancers. The goal is to see if it improves outcomes and understand how the body responds to this therapy.

Thyroid CancerEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Follicular Lymphoma: Golcadomide with Rituximab Study

We are comparing a new treatment combination to standard options for patients with relapsed or refractory follicular lymphoma. The study aims to see if this combination improves survival and quality of life.

Follicular LymphomaRelapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

New T Cell Therapy for Pediatric Blood Cancers

We are testing a modified T cell treatment for children with relapsed or hard-to-treat B-cell leukemia and lymphoma. The study aims to evaluate safety and effectiveness in helping these patients achieve remission.

Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Staphylococcus Aureus Bacteremia: Comparing Antibiotic Durations

We are studying whether 7 days of antibiotic treatment is as effective as 14 days for patients with uncomplicated Staphylococcus aureus bacteremia. This may help reduce antibiotic use and hospital stays.

Staphylococcus aureus Bacteremia≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Alzheimer's Disease: MK-2214 Study

We are testing a new medication, MK-2214, in people with early Alzheimer's disease to see if it may slow the progression of brain changes. The study will also evaluate the safety of this treatment compared to a placebo.

Alzheimer's Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology